My­lan Phar­ma­ceu­ti­cals faces an­oth­er re­call on in­sulin in­jec­tion pens

Vi­a­tris Phar­ma­ceu­ti­cals’ My­lan unit is fac­ing yet an­oth­er re­call on a batch of its in­sulin.

On Tues­day, Vi­a­tris — which was formed out of a $12 bil­lion merg­er be­tween My­lan and Pfiz­er’s Up­john unit back in 2020 — an­nounced that My­lan Phar­ma­ceu­ti­cals is vol­un­tar­i­ly re­call­ing one batch of in­sulin glargine in­jec­tion, 3 mL pre­filled pens due to po­ten­tial miss­ing la­bels.

The batch — num­bered BF21002895 — is not the brand­ed Sem­glee pen, but rather the un­brand­ed in­sulin pens that are pack­aged in car­tons of five. This batch is be­ing re­called due to the po­ten­tial for the la­bel to be miss­ing on some pens, and the FDA has been made aware of the re­call, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER